Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
Innate Pharma partnered with Sobi to license lacutamab for cutaneous T-cell lymphoma, triggering the initiation of the Phase 3 TELLOMAK-3 study for accelerated approval. Innate receives $75 million upfront and is eligible for up to $40 million in near-term milestones and $465 million in future payments, plus tiered royalties on net sales.
Key figures
- Drug Name
- lacutamab
- Phase Of Trial
- Phase 3
- Upfront payment usd
- 75000000
- Future milestones usd
- 465000000
- Near term milestones usd
- 40000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.